Regulation of Aspartyl-(Asparaginyl)-β-Hydroxylase Protein Expression and Function by Phosphorylation in Hepatocellular Carcinoma Cells

Diana L. Borgas*, Jin-Song Gao, Ming Tong, Nitin Roper, and Suzanne M. de la Monte

The Liver Research Center, Divisions of Gastroenterology and Neuropathology, and Departments of Medicine, Pathology, Neurology, and Neurosurgery, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA

**Background:** Asparaginyl-β-hydroxylase (AAH) promotes cell adhesion, migration, and invasion via Notch activation. AAH's expression is up-regulated by insulin/IGF signaling through PI3K-Akt, but its protein is independently regulated by GSK-3β. The multiple predicted GSK-3β phosphorylation sites suggest post-translational mechanisms may regulate AAH protein expression. **Methods:** Human Huh7 hepatoma cells were transfected with recombinant plasmids that expressed full-length N-terminal Myc-tagged (N-Myc-AAH) or C-terminal HA-tagged (C-HA-AAH) cDNA. Effects of IGF-1 on AAH protein were examined using cellular ELISAs, immunofluorescence, and Western blotting. Effects of kinase inhibitors relevant to AAH's predicted phosphorylation sites were studied. **Results:** IGF-1 stimulation increased AAH protein expression and shifted AAH's localization from the perinuclear zone to the cell periphery, including podocytes. Subsequently, Notch-1 intracellular domain was translocated to the nucleus, which is critical for Notch-1-modulated gene expression. Besides GSK-3β, inhibition of PKC, PKA, and CK2, which could potentially phosphorylate AAH, increased IGF-1-stimulated AAH protein. Finally, insulin and LiCl independently and additively increased long-term AAH protein expression. **Conclusion:** Insulin/IGF-1 stimulation of AAH and Notch are enhanced by inhibiting kinases that could phosphorylate AAH protein. Targeted manipulation of AAH's phosphorylation state may have therapeutic value for reducing AAH-Notch activation and attendant infiltrative growth of hepatocellular carcinomas. *Journal of Nature and Science,*** 1(4):e84, 2015

Hepatocellular carcinoma | insulin | IGF | aspartyl-asparaginyl-β-hydroxylase | Notch

**Introduction**

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide [1, 2], and among males in the United States [3]. Molecular mechanisms of HCC carcinogenesis include dysregulation of cell cycle checkpoints, apoptosis [4-6], and growth factor signaling [7-9]. Insulin/insulin-like growth factor (IGF) signaling are up-regulated in HCC [7, 9, 10]. Mechanisms include, gain-of-function mutations in phosphoinositide 3-kinase (PI3K) [11], impaired expression/function of phosphatase and tensin homolog [12], and over-expression of IGF-1 and IGF-1 receptor [9].

Aspartyl-asparaginyl-β-hydroxylase (AAH) is an important target of insulin/IGF signaling, and promotes cell migration and invasion [13-15] necessary for HCC cell infiltration and metastatic spread [16]. AAH is an ~86 kD [13] Type 2 transmembrane protein located in the endoplasmic reticulum (ER) [17, 18]. AAH is physiologically cleaved into a ~30-34 kD N-terminal fragment that is identical to Humbug (Junctate), a truncated isoform that binds calcium and promotes adhesion [19, 20], and a ~52-56 kD C-terminal fragment that has catalytic activity [21]. The C-terminal catalytic domain of AAH promotes cell motility by hydroxylating specific aspartate (Asp) and asparagine (Asn) residues contained within a consensus sequence of epidermal growth factor (EGF)-like domains, including those found in Notch and Jagged [16, 22, 23]. Correspondingly, AAH expression is functionally linked to Notch pathway activation in HCC [16].

Notch signaling starts by binding of Jagged (or Delta-like family of proteins) to Notch's extracellular domain, triggering two rapid cleavage events. The Notch extracellular domain is first cleaved from the transmembrane domain in a metalloprotease-dependent manner. This rapidly promotes the second cleavage event, which is protease-dependent and releases the Notch intracellular domain (NID) [24]. The NID then translocates to the nucleus where it complexes with the transcriptional activator CBF1, suppressor of hairless or lag-1 (CSL), and transcriptional co-activators of the mastermind-like family of proteins. The complex binds to CSL consensus sequences on DNA, displaces co-repressors and recruits additional co-activators to promote transcription of Notch targets such as hairy and enhancer of split-1 (HES-1) and hairy/ enhancer-of-split related with YRPW motif protein-1 (HEY-1) [25].

Insulin and IGF regulate AAH at both transcriptional and post-translational levels by signaling through PI3K [26]. With regard to post-translational processes, inhibition of glycogen synthase kinase-3β (GSK-3β) rather than activation of Akt is critical for increasing AAH protein, independent of its mRNA [26-28]. A potential role for direct phosphorylation of AAH as a means of regulating its protein expression and function was suggested by the findings that: 1) chemical or siRNA-targeted inhibition GSK-3β increases AAH protein expression and motility, while over-expression of constitutively active GSK-3β inhibits AAH protein expression and motility; 2) AAH protein has a number of consensus sequence sites for phosphorylation by GSK-3β, protein kinase A (PKA), protein kinase C (PKC), and casein kinase 2 (CK2); and 3) AAH migrates as a ~140 kD protein on SDS-PAGE, which is larger than its predicted ~86 kD mass. Therapeutic targeting of AAH protein could provide a novel means of regulating HCC's malignant infiltrative growth. Importantly, the potential exists to interfere with AAH's function by altering its phosphorylation, which may be important for Notch pathway activation. The present study characterizes insulin/IGF-1 stimulation of AAH, AAH phosphorylation, and Notch activation, and examines the roles of specific kinases in relation to these responses in Huh7 human HCC cells. Given the relatively high levels of endogenous AAH in HCC cells and inability to distinguish the N-terminal domain of AAH from Humbug, we generated N-tagged and C-tagged AAH cDNA constructs to conduct these experiments.

**Materials and Methods**

**Materials**

Recombinant IGF-1 was purchased from Sigma-Aldrich (St. Louis, MO, USA). pcDNA 3 vector, *Escherichia coli* DH5α cells, Dübcecco's Modified Eagle Medium, Lipopectamine 2000 Transfection Reagent, Hoechst 33342, and Ambex UltraRed were purchased from Invitrogen (Carlsbad, CA, USA). Non-essential

**Conflict of interest:** No conflicts declared.

*The work embodied in this manuscript partially fulfilled the requirements for a PhD degree in the Molecular Pharmacology and Physiology Program at Brown University.

Corresponding Author: Suzanne M. de la Monte, MD, MPH, Pierre Galletti Research Building, Rhode Island Hospital, 55 Claverick Street, Room 419, Providence, RI 02903. Tel: 401-444-7364; Fax: 401-444-2939; E-mail: Suzanne_DeLaMonte_MD@Brown.edu © 2015 by the Journal of Nature and Science (JNSCI).
amino acid mixture was purchased from Gibco-BRL (Grand Island, NY, USA). pcDNA 3 vector with a 6x Myc-tag was a gift from Dr. Y. Eugene Chin from Brown University (Providence, RI, USA) [29]. QIAquick Gel Extraction Kit and QIAprep Spin Miniprep Kit were purchased from Qiagen (Valencia, CA, USA). MaxiSorb plates, Opiplates (96-well), BD Falcon culture inserts, and Nunc culture supplies were obtained from Thermo Scientific (Rochester, NY, USA). Polyvinylidene fluoride membranes were purchased from Perkin-Elmer (Waltham, MA, USA). Myc antibody purchased from Cell Signaling Technologies (Danvers, MA, USA) and HA antibody purchased from Santa Cruz Biotechnologies (Dallas, TX, USA). Other fine chemicals were purchased from CalBiochem (San Diego, CA, USA). Histofix was purchased from Fisher Scientific (Pittsburgh, PA, USA) and SpectraMax M5 Microplate Reader from Molecular Dynamics (Sunnyvale, CA, USA). Histofix was purchased from Amresco (Solon, OH, USA) and Shandon CytoSpin 3 from Thermo Shandon (Pittsburgh, PA, USA). Other fine chemicals were purchased from CalBiochem (Carlsbad, CA, USA) or Sigma-Aldrich (St. Louis, MO, USA).

Recombinant AAH plasmid constructs.

The coding region of human AAH was amplified from a 293T cell cDNA library by the polymerase chain reaction (PCR) using the forward primer: 5'-CGGAATTCATGGCCCAGCTAGAATGCCA-3', reverse primer: 5'-CCGCTCGAGTTAAATGCTGGAGGCTGC-3' and Pfu DNA polymerase [13]. The AAH PCR product was digested with EcoRI and Xhol restriction enzymes and gel purified with the QIAquick Gel Extraction Kit. A pcDNA 3 vector with a 5'-end 6x Myc-tag insert was received as a gift and original pcDNA 3 vector was also engineered to contain a 5'-end 2x HA tag using the forward primer: 5'-TAAAGGACCCATTACGATGTTCTGACTAT-3' and reverse primer: 5'-TAAGGGTACACGTTGATAGTC-3'. The AAH PCR product was cloned into the Myc-modified (pCMV-N-Myc-AAH) or the HA-modified pcDNA 3 vector (pCMV-C-HA-AAH). The recombinant plasmids were transformed into Escherichia coli DH5α competent cells and positive clones cultured in Luria Broth media. The plasmids were purified with the QiAprep Spin Miniprep Kit and correct insert sequence and orientation was verified by DNA sequencing. Lastly, protein expression was verified in 293T and Huh7 cells by Western blot.

Cell culture.

Huh7 cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with heat-inactivated 5% fetal bovine serum (FBS), 10 mM non-essential amino acid mixture, and 2 mM L-glutamine in 5% CO2 at 37°C. Huh7 cells were transiently cultured with FBS, 10 mM non-essential amino acid mixture, and 2 mM L-glutamine in 5% CO2 at 37°C. Huh7 cells were transiently transfected with pcDNA-N-Myc-AAH, pcCMV-N-Myc-AAH or empty vector (EV) control at semi-confluency using Lipofectamine 2000 and co-transfected with a green fluorescent protein plasmid to monitor transfection efficiency. To determine the effects of growth-factor stimulation on recombinant AAH protein, 24-hr cultures expressing N-Myc-AAH or C-HA-AAH were placed in media with 1% FBS for 1 hr and treated with vehicle or stimulated with IGF-1 (50 ng/ml) for up to 60 min. To assess the role of kinase inhibition on IGF-1-stimulated AAH, Huh7 were pre-treated with inhibitors of GSK-3β (20 mM LiCl), casein kinase 2 (CK2; 5 µM TBCA/TBB), protein kinase A (PKA; 20 µM H-89), protein kinase C (PKC; 1 µM Gö6983), or MAPK/ERK (20 µM PD98059) for 4 hrs, followed by stimulation with IGF-1 (50 ng/ml). To assess the role of long-term of insulin stimulation and GSK-3β inhibition on N-Myc-AAH, cells were placed in 1% FBS media for 4 hrs, followed by insulin stimulation and 20 mM LiCl treatment for 16 hrs.

Protein studies.

Huh7 protein homogenates were prepared in radio-immunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.5, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 2 mM EGTA) in the presence of protease (1mM PMSF, 0.1 mM PCK, 1 mg/ml aprotinin, 1 mg/ml pepstatin A, 0.5 mg/ml leupeptin, 1 mM NaF, 1 mM Na3P2O7) and phosphatase (2 mM Na2VO3) inhibitors [32]. Protein homogenates were centrifuged at 14000xg for 10 min at 4°C and protein concentration in supernatant was measured by the bicinchoninic acid (BCA) assay. For Western blot analysis, 30 µg of protein were fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes that were subsequently incubated with SuperBlock in TRIS buffered saline (TBS) to prevent non-specific binding. After washing, the membranes were incubated with primary antibodies (0.1 µg/ml) overnight at 4°C. Immunoreactivities were detected with horseradish peroxidase (HRP)-conjugated secondary antibody, SuperSignal enhanced chemiluminescence reagents, and film autoradiography.

Cellular ELISA.

The cellular ELISA assay is an efficient method to rapidly and directly quantify protein under several treatment conditions in 96-well plate format [33]. Huh7 96-well cultures were fixed with Histofix, permeabilized with 0.05% saponin in TBS, and endogenous peroxidase activity blocked with 0.03% hydrogen peroxide in phosphate buffered saline (PBS). Non-specific protein binding was prevented by incubation with SuperBlock-TBS. After washing, the cultures were incubated with anti-p85-PI3K antibodies (0.1 µg/ml) overnight at 4°C and target protein immunoreactivity was detected with HRP-conjugated secondary antibodies and Amplex UltraRed fluorophore (Ex 530 nm/Em 590 nm). Ratios of target protein/cell density with Hoechst 33342 dye (Ex 360 nm/Em 460 nm) and fluorescence measured with SpectraMax M5 microplate reader. Ratios of target protein/cell density allowed for inter-well comparisons. 4-6 replicate cultures were analyzed for each experiment.

Figure 1: IGF-1 Stimulated AAH protein expression

Sub-confluent Huh7 cultures were stimulated with IGF-1 (10 ng/ml) for 0-60 min and used for Western blot analysis. (A) FB50+A85G6 monoclonal antibodies were used to detect AAH (3 cultures/time point). The blots were stripped and re-probed with rabbit polyclonal anti-p85-Pi3K as a loading control. (B) Western blot signals were quantified by digital imaging. The graph depicts the mean (± S.E.M.) relative levels of AAH protein (FB50+ A85G6/p85-Pi3K pixel intensity ratios) per point. Data were analyzed by 1-way ANOVA with the Dunnett post-hoc test (*P<0.05 and **P<0.01 relative to control (0 time point).
Cells were transfected with recombinant plasmid DNA carrying the full-length human AAH cDNA (CMV promoter) fused in-frame with either an N-terminal Myc tag (N-Myc-AAH) or C-terminal HA tag (C-HA-AAH). 24 hours after transfection, cultures stimulated with IGF-1 (10 ng/ml) for 0-60 min were subjected to Western blot analysis using antibodies to (A) Myc or FB50+A85G6, or (C) HA or A85G6. Blots were stripped and re-probed with antibodies to p85-PI3K (loading control). (B, D) Digital imaging was used to quantify the Western blot signals. Graphs depict calculated mean ± S.E.M. signal intensity ratios of AAH/p85-PI3K. Data were analyzed by 1-way ANOVA with the Dunnett post-hoc significance test (*P<0.05, **P<0.01, ***P<0.001; ****P<0.0001 relative to control (0 time point).
Further studies of Huh7 cells transfected with C-HA-AAH and stimulated with IGF-1 examined Notch-1’s intracellular domain (NID) expression and nuclear localization in relation to intracellular trafficking of C-HA-AAH. To accomplish this, transfected Huh7 cells were IGF-1 stimulated for 0-60 minutes and double-stained by immunofluorescence to detect HA and NID (Figure 4). Confocal microscopic imaging demonstrated that in un-stimulated cells (0 min), C-HA-AAH was localized in the perinuclear and peri-nuclear zones (Figure 4A) while low levels of NID immunoreactivity were detected in the nuclear and peri-nuclear zones (Figure 4F). Within 10 minutes of IGF-1 stimulation, C-HA-AAH immunoreactivity shifted to the cell periphery and podocytes (Figure 4B), whereas NID immunoreactivity was reduced and scarcely detectable (Figure 4G). At the 30-minute time point, C-HA-AAH immunoreactivity was detected in both podocytes (although less than at 10 minutes) as well as in a particulate pattern corresponding to the ER and microsomal structures (Figure 4C), whereas NID immunoreactivity was still scarcely detectable. However, at the 60-minute time point, C-HA-AAH immunoreactivity returned to the nuclear and peri-nuclear zones (Figure 4D), and NID was abundantly present in the nucleus (Figure 4I). Merged images revealed low levels of nuclear NID from 0 to 30 minutes after IGF-1 stimulation, and abundant nuclear NID immunoreactivity in cells with high levels of C-HA-AAH localized to the nucleus and peri-nuclear zones (Figure 4N).
### Table 1: Differential effects of kinase inhibitors on short-term IGF-1 stimulated AAH immunoreactivity

<table>
<thead>
<tr>
<th>Protein</th>
<th>IGF1 Stimulation</th>
<th>Kinase Inhibitor</th>
<th>IGF-1 x Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F-Ratio</td>
<td>P-Value</td>
<td>F-Ratio</td>
</tr>
<tr>
<td>A85G6</td>
<td>13.99</td>
<td>&lt;0.0003</td>
<td>35.18</td>
</tr>
<tr>
<td>A85E6</td>
<td>12.41</td>
<td>&lt;0.0001</td>
<td>59.28</td>
</tr>
<tr>
<td>FB50</td>
<td>3.57</td>
<td>N.S.</td>
<td>57.67</td>
</tr>
<tr>
<td>β-Actin</td>
<td>1.40</td>
<td>N.S.</td>
<td>66.43</td>
</tr>
</tbody>
</table>

Huh7 human hepatoma cells grown in 96-well micro-cultures were pre-treated with vehicle (control), LiCl, TBCA, Go6983, H-89, or PD98059 to inhibit GSK-3β, CK2, pan-PKC, PKA, or MEK, and then stimulated for 15 minutes with 10 ng/ml IGF-1. Cellular ELISAs measured immunoreactivity to AAH (A85G6-C-terminus; A85E6 and FB50-N-terminus) and β-actin. Data were analyzed by Two-way ANOVA. Corresponding graphs with post-hoc Fisher LSD results are shown in Figure 5.

### Table 2: Differential effects of kinase inhibitors on long-term IGF-1 stimulated AAH immunoreactivity

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>IGF-1 Stimulation</th>
<th>Kinase Inhibitor</th>
<th>IGF-1 x Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F-Ratio</td>
<td>P-Value</td>
<td>F-Ratio</td>
</tr>
<tr>
<td>H-89</td>
<td>16.95</td>
<td>0.083</td>
<td>0.21</td>
</tr>
<tr>
<td>PD98059</td>
<td>11.84</td>
<td>0.0003</td>
<td>49.81</td>
</tr>
<tr>
<td>LiCl</td>
<td>75.57</td>
<td>&lt;0.0001</td>
<td>3.69</td>
</tr>
<tr>
<td>Go6983</td>
<td>9.09</td>
<td>&lt;0.0001</td>
<td>79.37</td>
</tr>
<tr>
<td>TBCA</td>
<td>53.54</td>
<td>&lt;0.0001</td>
<td>13.55</td>
</tr>
</tbody>
</table>

Huh7 human hepatoma cells grown in 96-well micro-cultures were pre-treated with vehicle (control), LiCl, TBCA, Go6983, H-89, or PD98059 to inhibit GSK-3β, CK2, pan-PKC, PKA, or MEK, and then stimulated for 60 minutes with 10 ng/ml IGF-1. Cellular ELISAs measured immunoreactivity to AAH (A85G6-C-terminus; A85E6 and FB50-N-terminus) and β-actin. Data were analyzed by Two-way ANOVA. Corresponding graphs with post-hoc Fisher LSD results are shown in Figure 6.

Figure 6. Time course of kinase inhibitor modulation of AAH immunoreactivity in IGF-1 stimulated cells: Huh7 96-well cultures were pre-treated with vehicle (control), LiCl, TBCA, Go6983, H-89, or PD98059 for 4 hrs and then stimulated with IGF-1 for 0-60 min. Immunoreactivity to (A) AAH-A85G6 and (B) β-Actin was measured by cellular ELISA with results normalized to Hoechst H33342 fluorescence (cell density). Graphs depict the mean ± S.E.M of 4 replicate cultures per group. Inter-group comparisons were made using two-way ANOVA (Table 2) and the post hoc Fisher’s Least Significance Difference tests (*p<0.05; **p<0.01; ***p<0.001; and ****p<0.0001).
Kinase inhibitor effects on endogenous AAH protein expression.

Given the finding that AAH protein has multiple phosphorylation motifs corresponding to mainly GSK-3β, but also PKA, PKC, and CK2, we conducted further studies to examine endogenous AAH protein expression following treatment with specific kinase inhibitors. Huh7 cells seeded in 96-well cultures were treated with inhibitors of GSK-3β (LiCl) [35,36], CK2 (TBCA/TBB), PKA (H89), PKC (G66983), MEK (PD98059), or CK1 (D4476), and then stimulated with IGF-1 or nothing (serum-free media treated) for 15 minutes. PD98059 and D4476 served as controls since there are no CK1 or MEK phosphorylation sites on AAH. Immunoreactivity to AAH was measured by cellular ELISA using the A85G6 AAH monoclonal antibody (catalytic domain). Parallel studies measured β-actin expression. Immunoreactivity was normalized to H33342 fluorescence, which correlates with cell density [30,35]. ANOVA tests demonstrated significant differences in AAH (F=18.72; P=0.0042) (Figure 5A) and β-actin (F=18.44; P<0.0001) (Figure 5B) expression in IGF-1 stimulated, kinase inhibitor treated relative to control (vehicle-treated unstimulated or stimulated) (Table 1). Post hoc Fisher’s LSD test showed AAH was significantly increased by IGF-1 stimulation and pre-treatment with LiCl (P<0.05), H-89 (P<0.0001), and G66983 (P<0.01), but not TBCA or PD98059 (Figure 5). Note that AAH is predicted to have GSK-3β, PKA, and PKC phosphorylation sites [30]. Both basal and IGF-1 stimulated β-Actin levels increased in cultures treated with G66983 (P<0.01) or PD98059 (P<0.0001), and decreased in IGF-1 versus vehicle stimulated H-89-treated cultures (P<0.05). Therefore, except for the G66983 effects, the responses with respect to AAH expression were dissimilar from those of β-actin, possibly reflecting specificity (Figure 5).

Further studies were performed using cellular ELISAs to characterize the time course of IGF-1 stimulated AAH protein (A85G6) in the presence or absence of LiCl to inhibit GSK-3β, TBCA to suppress CK2, G66983 to inhibit pan-PKC, H-89 to inhibit PKA, or PD98059 to inhibit MEK (Table 2; Figure 6). Four replicate cultures were assayed at each time point. Those studies demonstrated significant inter-group differences in AAH protein expression in cells stimulated with IGF-1 and treated with LiCl (F=8.92; 0.0008; Figure 6A), TBCA (F=9.18; P=0.032; Figure 6B), G66983 (F=6.42; P=0.0001; Figure 6C), H89 (F=25.81; P=0.016; Figure 6D), and PD98059 (F=24.42; P<0.0001; Figure 6E). LiCl (0.05<P<0.0001), G66983 (P<0.0001), and PD98059 (Figure 6E) pre-treatments significantly increased both basal and IGF-1 stimulated AAH. The responses to LiCl and G66983 were sustained throughout the time course (60 min), whereas for PD98059, the effect was only observed during the early time points. In contrast, the main effect of TBCA was to increase AAH expression at intermediate time points (15 and 30 min), and not the early or latest time points. Reponses to H-89 were significant at the 10- ad 60-minute time points, but overall, the effects of H-89+IGF-1 were modest. In essence, inhibition of GSK-3β, PKA, or MEK phosphorylation sites was observed in IGF-1 stimulated, LiCl-treated cultures throughout all time points (Figures 7E-7H). The effects of TBB (CK2 inhibitor) were more robust (Figure 7M-7P) compared with TBCA (Figure 6B). The responses to H-89 were discordant with the findings by cellular ELISA, and instead suggest that inhibition of PKA prominently increases AAH protein expression in the earliest time periods following IGF-1 stimulation. In general, the increases in AAH immunoreactivity were distributed throughout the cytoplasm as well as the perinuclear zone. The pattern of diffuse cytoplasmic staining was reticular or particulate, consistent with the known microsomal and mitochondrial distributions of AAH.
Effects of LiCl-GSK-3β inhibition on insulin-stimulated AAH in HuH7 cells transfected with C-HA-AAH or N-Myc-AAH recombinant cDNA plasmids.

In the final experiment, we focused on the role of GSK-3β in relation to AAH expression since most of AAH’s predicted phosphorylation sites have GSK-3β consensus sequences, and previous studies showed that GSK-3β could directly phosphorylate AAH [30, 31]. We took advantage of our C-HA-AAH and N-Myc-AAH constructs for this experiment because most of the GSK-3β phosphorylation sites are located in the N-terminus of this Type 2 transmembrane protein. We used Western blot analysis to examine long-term effects of insulin stimulation on AAH protein, in the presence or absence of LiCl pre-treatment. In cells transfected with N-Myc-AAH or C-HA-AAH, both insulin and LiCl increased AAH protein expression relative to vehicle (Figures 8A-8B). Similar results were obtained using monoclonal antibodies to the C-terminus (A855G) or N-terminus (FB-50) of AAH. Correspondingly, immunofluorescence staining and confocal imaging demonstrated higher levels of AAH immunoreactivity in insulin-stimulated, LiCl-treated versus vehicle treated cells (Figures 8C-8D), and a more prominent nuclear to perinuclear localization of AAH compared with short-term stimulation effects (Figures 8E-8H).

Discussion

Overarching concept.

In HCCs, insulin and IGF signaling pathways are up-regulated [9, 36, 37]. AAH is over-expressed in HCC due to its regulation by insulin/IGF through both Erk-MAPK and PI3K-Akt pathways. Since AAH has functional roles in regulating cell adhesion, motility, and invasion [32], its over-expression HCCs could account for the relentless and aggressive infiltrative growth of these neoplasms. Correspondingly, AAH protein expression is abundantly expressed at infiltrating HCC tumor margin, which could be critical for mediating invasion of surrounding tissue and intrahepatic dissemination of HCC [38]. Although AAH stimulation occurs at the mRNA level, previous studies highlight the importance of distinct regulators of AAH’s protein that are independent of gene transcription. This phenomenon was made evident in studies showing that treatment of neuroblastoma cells with LiCl increased AAH’s protein but had no effect on its mRNA [26]. Further studies pointed to direct roles of GSK-3 regulation of AAH protein such that high levels of GSK-3β activity reduce AAH protein, while inhibition of GSK-3β increases AAH protein expression, again without altering the mRNA levels [30]. It was therefore logical that activation of insulin/IGF-1 signaling networks through PI3K-Akt could have long-term effects on AAH’s mRNA, and short-term effects on AAH’s protein due to PI3K-Akt inhibition of GSK-3β (Figure 9).

The next consideration was to determine if short-term GSK-3β-mediated regulation of AAH protein could be due to direct effects of AAH protein phosphorylation by GSK-3β. Subsequence analysis of AAH protein indicated the presence of multiple potential phosphorylation sites, including those with consensus sequences corresponding to GSK-3β [30]. In addition, we determined that AAH has other potential phosphorylation sites with consensus sequences for PKA, PKC or CK2. Most of the predicted phosphorylation sites are located in the N-terminal region of the protein. In vitro kinase assays, metabolic labeling studies, and immunoprecipitation/Western blot analysis demonstrated that AAH could be phosphorylated by GSK-3β [30]. The present work was designed to characterize AAH protein expression in insulin/IGF-1 stimulated HCC cells to further examine the consequences of its phosphorylation, including the likely impact on Notch signaling.
Insulin/IGF-1 stimulation of AAH protein.
Initial studies confirmed that IGF-1 stimulation increases endogenously expressed AAH protein within 5 minutes and sustained for at least 60 minutes. However, due to the relatively low signal, the studies were extended using Huh7 HCC cells transfected with C-HA-AAH or N-Myc-AAH in which gene expression was regulated by a CMV promoter. In a separate study, we showed that Huh7 cells transfected with C-HA-AAH or N-Myc-AAH had significantly increased AAH expression, catalytic activity, HES-1 expression, and directional motility relative to mock-transfected control cells [39]. As observed with respect to the endogenously expressed protein, AAH accumulated in response to short-term IGF-1 stimulation. In addition to increasing the signal for monitoring AAH protein, the approach enabled us to track cellular expression and distribution of AAH’s N- and C-terminal cleavage products with specific HA and Myc epitope antibodies. In Huh7 and other HCC lines, this strategy is important because, under physiological conditions, AAH is rapidly cleaved, resulting in the predominant ~56 kD C-terminal catalytic domain-containing fragment as observed by Western blot analysis of IGF-1 stimulated, non-transfected Huh7 cells. In contrast, in transfected cells expressed a ~140 kD AAH-immunoreactive protein (HA-tagged or Myc-tagged) that accumulated over time. The larger than predicted 86 kD protein corresponds with effects of post-translational modification, such as by phosphorylation.

Shifts in subcellular localizations of AAH and Notch-1 following IGF-1 stimulation.
Previous studies linked AAH expression and hydroxylase activity to Notch-activated signaling [16]. In HCC, Notch-1 is the dominant isoform. Since hydroxylation of Notch by AAH requires the proteins to interact or be in close proximity, we anticipated that AAH protein would traffic from its perinuclear localization to the cell periphery or surface to interact with and hydroxylate Notch. Furthermore, we anticipated that the C-terminal fragment which contains the catalytic domain would likely move to the cell periphery in response to IGF-1 stimulation. Correspondingly, in cells transfected with recombinant AAH, IGF-1 stimulation resulted in the trafficking of C-HA-AAH from the perinuclear zone to the cell periphery, including podocytes, followed by nuclear accumulation of the Notch intracellular domain (NID). These results are consistent with our hypothesis that IGF-1 stimulation of AAH protein mediates Notch nuclear translocation and attendant regulation of gene expression.

IGF-1 plus kinase inhibitor modulation of AAH protein expression.
Sub-sequence analysis of AAH protein predicts the presence of 17 sites for GSK-3β mediated phosphorylation, as well as several others corresponding to PKA, PKC, or CK2 phosphorylation sites [30]. Given the results obtained using LICl to inhibit GSK-3β, we next assessed whether other relevant kinase inhibitors would also increase AAH protein expression and alter its sub-cellular localization in response to IGF-1 stimulation. The combined results obtained by cellular expression, immunofluorescence/confocal microscopy demonstrated that, in addition to GSK-3β, PKA, PKC and CK2 inhibitors also increased AAH protein in IGF-1 stimulated Huh7 cells. However, the time course effects differed in that the PKA and CK2 inhibitor effects were more limited whereas the GSK-3β and PKC inhibitor effects were sustained. The early transient stimulatory effects of PD98059 on AAH protein are not fully understood. However, inhibition of MEK leads to oxidative stress and oxidative stress was previously shown to stimulate AAH expression via HIF-1α activated signaling [40].

Long-term effects of GSK-3β inhibition and insulin stimulation on AAH expression.
To assess the differential roles of insulin or IGF-1 stimulation and GSK-3β inhibition on AAH protein expression, we examined AAH expression Huh7 cells transfected with C-HA-AAH or N-Myc-AAH and treated with LiCl, with or without insulin stimulation. Since this approach enabled abundant expression of full-length AAH, our ability to evaluate responses was not compromised by rapid cleavage and poor detection of relatively small amounts of protein. The studies demonstrated that LiCl inhibition of GSK-3β was sufficient to increase AAH protein levels in the absence of insulin (or IGF-1) stimulation. However, progressively higher levels of ~140 kDa AAH were detected in insulin stimulated, followed by insulin+LiCl treated cultures, indicating additive effects of trophic factor stimulation and GSK-3β inhibition. Mechanistically, the additive effect of LiCl with insulin could have been due to reduced cleavage/degradation and increased stabilization of AAH protein. Consequences would include increased activation of Notch signaling and enhanced cell motility, as previously demonstrated in other cell types [22, 41].

Conclusions: The findings suggest that insulin/IGF signaling promotes the trafficking of AAH to the plasma where it may facilitate the activation of Notch signaling networks. The effects may occur through the post-translational regulation of AAH mainly by GSK-3β, CK2, and PKC. These proteins have the potential to serve as promising targets for controlling aggressive growth of HCC.

Acknowledgements
Supported by AA11431, AA12908 and 5T32DK060415-10 from the National Institutes of Health.


